Natera, Inc. Common Stock

Day range

$400.67 – $407.88

Open

$404.71

Prev close

$403.95

Volume

438.73K

Market cap

$58.23B

Shares out

144.14M

P/E

—

P/S

21.51

P/B

31.97

P/FCF

691.56

ROE

-10.6%

ROA

-7.2%

Debt/Equity

0.04

Div yield

0.00%

As of Oct 23, 2026

• Director departureJul 6, 2026

  On July 1, 2026, Monica Bertagnolli notified the Board of Directors (the "Board") of Natera, Inc. ("Natera" or the "Company") of her intention to resign as a member of the Board and any committees of the Board, effective July 1, 2026, due to her new position with the National Academy of Medicine.

• Annual meeting resultsJun 16, 2026

  On June 11, 2026, at the Annual Meeting, the Company's stockholders voted on five proposals... The tabulation of the stockholders' votes on each proposal brought before the Annual Meeting is as follows: Proposal 1: The election of three directors to serve as Class II directors until the 2029 annual meeting of stockholders, and the election of one director to serve as a Class I director until the 2028 annual meeting of stockholders.

• Director appointmentJun 5, 2026

  The Board of Directors (the "Board") of Natera, Inc., a Delaware corporation (the "Company") (i) increased the size of the full Board from eleven to twelve members and (ii) appointed Thomas Lynch as a member of the Board, in each case effective as of June 2, 2026. Dr. Lynch will serve as a Class I director, with an initial term expiring at the 2028 annual meeting of stockholders. The Board determined that Dr. Lynch qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of The Nasdaq Stock Market. The Board has appointed Dr. Lynch to the Human Capital Committee of the Board.

• Executive compensation changeApr 1, 2026

  In connection with his appointment to the Board, Dr. Rubin will be entitled to receive cash and equity compensation consistent with that of the Company's other non-employee directors. The initial equity award granted to Dr. Rubin will vest as to one-third of the shares covered by such award on each of March 26, 2027, 2028, and 2029.

• Preliminary resultsJan 12, 2026

  On January 11, 2026, Natera, Inc. (the "Company") issued a press release announcing preliminary financial results for its fourth quarter and fiscal year ended December 31, 2025.

Days to cover

3.2

Short interest

6.36M

Avg volume

1.98M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
  positiveZacks Investment Research· Oct 26, 2026
• Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.
  negativeThe Motley Fool· Oct 25, 2026
• Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
  neutralThe Motley Fool· Oct 22, 2026
• Natera Partners With TransCode to Advance Colorectal Cancer Trial
  positiveZacks Investment Research· Oct 21, 2026
• Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
  neutralZacks Investment Research· Oct 19, 2026